Interpace OTC Stock Financials

IDXG
 Stock
  

USD 1.15  0.14  10.85%   

Interpace Biosciences Average Assets are projected to decrease significantly based on the last few years of reporting. The past year's Average Assets were at 41.44 Million. The current year Enterprise Value is expected to grow to about 41.8 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (32.5 M).
  
With this module, you can analyze Interpace financials for your investing period. You should be able to track the changes in Interpace Biosciences individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Understanding current and past Interpace Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Interpace Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Interpace Biosciences' assets may result in an increase in income on the income statement.

Revenues

28.42 Million

The financial analysis of Interpace Biosciences is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Interpace Biosciences includes many different criteria found on its balance sheet. For example, investors should never minimize Interpace Biosciences' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Interpace Biosciences' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Interpace Biosciences.

Interpace Biosciences Cash

Chance Of Financial Distress
Less than 42
Interpace Biosciences has less than 42 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Interpace Biosciences otc stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Interpace Biosciences' official financial statements usually reflect Interpace Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Interpace Biosciences. For example, before you start analyzing numbers published by Interpace accountants, it's critical to develop an understanding of what Interpace Biosciences' liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Interpace Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Interpace Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Interpace Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Interpace Biosciences. Please utilize our Beneish M Score to check the likelihood of Interpace Biosciences' management to manipulate its earnings.

Interpace Biosciences Company Summary

Interpace Biosciences competes with Steven Madden, Samsonite International, MISUMI, Snap On, and ASICS. Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.
InstrumentUSA OTC Stock View All
ExchangeOTCQX Exchange
CIK Number0001054102
ISINUS46062X3035
RegionNorth America
Business AddressMorris Corporate Center
SectorHealth Care Providers & Services
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.interpace.com
Phone855 776 6419
CurrencyUSD - US Dollar
You should never invest in Interpace Biosciences without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Interpace OTC Stock, because this is throwing your money away. Analyzing the key information contained in Interpace Biosciences' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Interpace Biosciences Key Financial Ratios

Generally speaking, Interpace Biosciences' financial ratios allow both analysts and investors to convert raw data from Interpace Biosciences' financial statements into concise, actionable information that can be used to evaluate the performance of Interpace Biosciences over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Interpace Biosciences reports annually and quarterly.

Interpace Biosciences Key Balance Sheet Accounts

201720182019202020212022 (projected)
Receivables2.53 M3.44 M9.48 M10.2 M11.73 M11.59 M
Accounts Payable2.33 M391 K1.06 M4.81 M5.53 M4.51 M
Total Assets41.78 M53.6 M48.44 M69.05 M79.41 M87.05 M
Current Assets4.24 M19.81 M17.72 M16.37 M18.82 M19.32 M
Assets Non Current33.79 M13.41 M35.03 M31.56 M26.26 M31.9 M
Cash and Equivalents602 K15.2 M6.07 M2.32 M2.67 M2.74 M
Total Debt8.4 M7.91 M5.59 M3.54 M12.6 M11.2 M
Debt Non Current7.23 M7.91 M5.59 M3.54 M12.6 M11.12 M
Shareholders Equity6.53 M39.87 M32.94 M39.2 M45.08 M43.92 M
Total Liabilities35.25 M13.73 M15.5 M29.85 M34.33 M43.13 M
Current Liabilities16.24 M8.09 M8.49 M17.3 M19.89 M25.77 M

Interpace Biosciences Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Interpace Biosciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Direct Expenses6.64 M7.36 M10.2 M15.89 M18.27 M18.75 M
Consolidated Income(12.22 M)(12.7 M)(26.74 M)(26.45 M)(14.94 M)(16.12 M)
Cost of Revenue7.36 M10.2 M15.89 M21.67 M23.37 M29.19 M
Gross Profit8.54 M11.7 M8.33 M10.72 M17.95 M15.16 M
Interest Expense433 K331 K440 K549 K496 K718.95 K
Net Income(8.33 M)(12.22 M)(12.19 M)(26.73 M)(30.74 M)(31.54 M)
Operating Expenses20.43 M22.81 M34.81 M37.28 M32.28 M30.42 M
Operating Income(6.44 M)(6.29 M)(12.12 M)(26.42 M)(30.39 M)(32.79 M)
Revenues13.09 M15.9 M21.9 M24.08 M27.69 M28.42 M
Income Tax Expense(395 K)18 K(28 K)53 K(667 K)(719.66 K)

Interpace Biosciences Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Interpace Biosciences. It measures of how well Interpace is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Interpace Biosciences brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Interpace had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Interpace Biosciences has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Depreciation Amortization and Accretion3.69 M3.8 M4.52 M5.5 M5.37 M5 M
Net Cash Flow or Change in Cash and Cash Equivalents14.6 M(9.13 M)(3.75 M)1.05 M(58 K)(62.58 K)
Issuance Purchase of Equity Shares23.05 M(9 K)6.44 M382 K335 K343.82 K
Issuance Repayment of Debt Securities(21.6 M)(1.33 M)(3.02 M)(3 M)8.76 M9.46 M
Net Cash Flow from Financing1.23 M29.89 M(9 K)29.16 M26.24 M28.31 M
Net Cash Flow from Operations(8.94 M)(15.26 M)(8.67 M)(18.96 M)(21.8 M)(22.37 M)
Share Based Compensation1.06 M2.27 M1.53 M2.24 M1.37 M1.49 M

Interpace Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Interpace Biosciences's current stock value. Our valuation model uses many indicators to compare Interpace Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Interpace Biosciences competition to find correlations between indicators driving Interpace Biosciences's intrinsic value. More Info.
Interpace Biosciences is currently regarded as number one stock in short ratio category among related companies. It is currently regarded as number one stock in working capital category among related companies . Interpace Biosciences Working Capital is projected to decrease significantly based on the last few years of reporting. The past year's Working Capital was at (3.52 Million). Comparative valuation analysis is a catch-all model that can be used if you cannot value Interpace Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Interpace Biosciences' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Interpace Biosciences' earnings, one of the primary drivers of an investment's value.

Interpace Biosciences Systematic Risk

Interpace Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Interpace Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Interpace Biosciences correlated with the market. If Beta is less than 0 Interpace Biosciences generally moves in the opposite direction as compared to the market. If Interpace Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Interpace Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Interpace Biosciences is generally in the same direction as the market. If Beta > 1 Interpace Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
.

About Interpace Biosciences Financials

What exactly are Interpace Biosciences Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Interpace Biosciences' income statement, its balance sheet, and the statement of cash flows. Potential Interpace Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Interpace Biosciences investors may use each financial statement separately, they are all related. The changes in Interpace Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Interpace Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Interpace Biosciences is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Interpace has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Interpace Biosciences December 6, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Interpace Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Interpace Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Interpace Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Interpace OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Interpace Biosciences's daily price indicators and compare them against related drivers.
Information Ratio(0.05)
Maximum Drawdown42.78
Value At Risk(10.85)
Potential Upside18.92
Please see Risk vs Return Analysis. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for analysis

When running Interpace Biosciences price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Please note, there is a significant difference between Interpace Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Interpace Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpace Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.